Organization Opens New Offices in Belgium and Ireland
STAMFORD, CT—JUNE 25, 2012—ArisGlobal, a provider of solutions to the life science industry, announced the opening of two new offices in Antwerp, Belgium and Dublin, Ireland.
These new offices will allow the company to continue its growth and expansion in several product areas including pharmacovigilance and risk management, clinical data management and operations, regulatory affairs, and medical information management.
“We continue to grow with the addition of new customers and the development of new products and offerings. This expansion has created the need for an even broader global presence and new space in several regions of the world,” commented Vice President of European Operations, Simon Sparkes. “This expansion will help us to deliver added value to our customers and further execute on our vision of a suite of integrated life science software and services meeting the diverse needs of organizations around the world.”
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Fast Tracks Johnson & Johnson’s Nipocalimab for Fetal Neonatal Alloimmune Thrombocytopenia
March 27th 2024Johnson & Johnson is moving forward with a pair of Phase III trials of nipocalimab to reduce the risk of fetal neonatal alloimmune thrombocytopenia in alloimmunized pregnant patients.